Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease

Journal of Human Hypertension volume 26, pages 502–506 (2012)Cite this article

Abstract

Hypertension is a major risk factor for the development and progression of chronic kidney disease (CKD). Mineralocorticoid receptor antagonists (MRAs) are effective in the management of resistant hypertension but are not widely used in CKD because of the risk of hyperkalemia. We retrospectively evaluated the long-term effects and safety of MRAs added to a pre-existing antihypertensive regimen in subjects with resistant hypertension associated with stage 3 CKD. In all, 32 patients were treated with spironolactone and 4 with eplerenone for a median follow-up of 312 days. MRAs induced a significant decrease in systolic blood pressure from 162±22 to 138±14 mm Hg (P<0.0001) and in diastolic blood pressure from 87±17 to 74±12 mm Hg (P<0.0001). Serum potassium increased from 4.0±0.5 to 4.4±0.5 mEq l−1 (P=0.0001), with the highest value being 5.8 mEq l−1. The serum creatinine increased from 1.5±0.3 to 1.8±0.5 mg dl−1 (P=0.0004) and the estimated glomerular filtration rate decreased from 48.6±8.7 to 41.2±11.5 ml min−1 per 1.73 m2 (P=0.0002). One case of acute renal failure and three cases of significant hyperkalemia occurred. MRAs significantly reduced blood pressure in subjects with resistant hypertension associated with stage 3 CKD, although close biochemical monitoring is recommended because of an increased risk of hyperkalemia and worsening of renal function.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G . Urinary protein excretion rate is the best independent predictor of esrf in non-diabetic proteinuric chronic nephropathies. ‘Gruppo italiano di studi epidemiologici in nefrologia’ (gisen). Kidney Int 1998; 53: 1209–1216.

    Article  CAS  Google Scholar 

  2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of high blood pressure. The JNC 7 report. JAMA 2003; 289: 2560–2572.

    Article  CAS  Google Scholar 

  3. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: S1–S290.

    Google Scholar 

  4. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY . Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296–1305.

    Article  CAS  Google Scholar 

  5. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE . Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139: 244–252.

    Article  CAS  Google Scholar 

  6. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005; 16: 2170–2179.

    Article  CAS  Google Scholar 

  7. Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G et al. Independent and additive impact of blood pressure control and angiotensin ii receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial: clinical implications and limitations. J Am Soc Nephrol 2005; 16: 3027–3037.

    Article  CAS  Google Scholar 

  8. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007; 49: 839–845.

    Article  CAS  Google Scholar 

  9. Nishizaka MK, Zaman MA, Calhoun DA . Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16: 925–930.

    Article  CAS  Google Scholar 

  10. Schepkens H, Vanholder R, Billiouw JM, Lameire N . Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001; 110: 438–441.

    Article  CAS  Google Scholar 

  11. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130: 461–470.

    Article  CAS  Google Scholar 

  12. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, Tarnow L et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005; 68: 2829–2836.

    Article  CAS  Google Scholar 

  13. Bianchi S, Bigazzi R, Campese VM . Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70: 2116–2123.

    Article  CAS  Google Scholar 

  14. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ . Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin ii receptor blocker. Clin J Am Soc Nephrol 2006; 1: 256–262.

    Article  CAS  Google Scholar 

  15. Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ . Change in proteinuria after adding aldosterone blockers to ace inhibitors or angiotensin receptor blockers in ckd: a systematic review. Am J Kidney Dis 2008; 51: 199–211.

    Article  Google Scholar 

  16. Bomback AS, Klemmer PJ . The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3: 486–492.

    Article  CAS  Google Scholar 

  17. MacGregor GA, Markandu ND, Rotellar C, Smith SJ, Sagnella GA . Different effect of nifedipine in normotensive and hypertensive individuals: a functional anomaly of vascular smooth muscle in essential hypertension? Rev Esp Cardiol 1983; 36: 473–477.

    CAS  PubMed  Google Scholar 

  18. Ahuja TS, Freeman Jr D, Mahnken JD, Agraharkar M, Siddiqui M, Memon A . Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. Am J Nephrol 2000; 20: 268–272.

    Article  CAS  Google Scholar 

  19. Bakris GL, Weir MR . Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160: 685–693.

    Article  CAS  Google Scholar 

  20. Arima S . Aldosterone and the kidney: rapid regulation of renal microcirculation. Steroids 2006; 71: 281–285.

    Article  CAS  Google Scholar 

  21. Loutzenhiser R, Griffin KA, Bidani AK . Systolic blood pressure as the trigger for the renal myogenic response: protective or autoregulatory? Curr Opin Nephrol Hypertens 2006; 15: 41–49.

    Article  Google Scholar 

  22. Wright Jr JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J et al. African American Study of Kidney Disease and Hypertension Study Group: effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421–2431.

    Article  CAS  Google Scholar 

  23. Khosla N, Kalaitzidis R, Bakris GL . Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009; 30: 418–424.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by NHLBI RO1-HL79040 (David A Calhoun) and T32 HL007457 (Roberto Pisoni)

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, SC, USA

    R Pisoni

  2. Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA

    M C Acelajado, T Dudenbostel, L J Dell'Italia, S Oparil & D A Calhoun

  3. Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA

    F R Cartmill & S S Cofield

Authors
  1. R Pisoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M C Acelajado
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F R Cartmill
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T Dudenbostel
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L J Dell'Italia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S S Cofield
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Oparil
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D A Calhoun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Pisoni.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pisoni, R., Acelajado, M., Cartmill, F. et al. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease. J Hum Hypertens 26, 502–506 (2012). https://doi.org/10.1038/jhh.2011.60

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jhh.2011.60

Keywords

This article is cited by

Search

Advanced search

Quick links